MIR5695

Across TCGA pan-cancer cohorts, MIR5695 RNA is linked to patient survival in 20 of 34 cancer types, making it the most broadly survival-associated MIR5695 data layer.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher MIR5695 RNA is associated with better overall survival. In most high-consensus cancer types, elevated MIR5695 expression acts as an unfavorable survival marker, although some lineages such as STAD and PAAD show a favorable association.

STAD, ACC, and CHOL are the cancer types where MIR5695 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Quartile	II,III,IV	0.809	0.586	<.001	94	view →
ACC	OS	Tertile	All	0.315	0.821	<.001	72	view →
CHOL	OS	Tertile	III,IV	0.136	0.859	.003	45	view →
DLBC	DFS	Tertile	III,IV	0.137	0.761	.014	27	view →
PAAD	OS	Quartile	All	0.632	0.256	.003	24	view →
COAD	DFS	Tertile	II,III,IV	0.284	0.501	.002	24	view →
CESC	DFS	Median	II,III,IV	0.685	0.832	.010	18	view →
KICH	DFS	Tertile	All	0.563	0.914	.023	15	view →
OV	DFS	Quartile	IV	0.252	0.483	.028	14	view →
LGG	OS	Median	All	0.926	0.860	.007	14	view →
LAML	DFS	Tertile	All	0.749	0.405	.012	12	view →
KIRP	OS	Quartile	All	0.860	0.955	<.001	10	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 20 lineages.

MIR5695–STAD (OS)

Open the STAD breakdown →